Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Citius Pharmaceuticals, Inc. (CTXR)

1.19   0.03 (2.59%) 11-25 13:00
Open: 1.19 Pre. Close: 1.16
High: 1.19 Low: 1.13
Volume: 155,308 Market Cap: 174(M)

Technical analysis

as of: 2022-11-25 1:56:12 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 1.42     One year: 1.66
Support: Support1: 1.09    Support2: 1
Resistance: Resistance1: 1.22    Resistance2: 1.42
Pivot: 1.09
Moving Average: MA(5): 1.15     MA(20): 1.09
MA(100): 1.1     MA(250): 1.26
MACD: MACD(12,26): 0     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 73     %D(3): 76.1
RSI: RSI(14): 61.8
52-week: High: 2  Low: 0.83
Average Vol(K): 3-Month: 496 (K)  10-Days: 468 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ CTXR ] has closed below upper band by 2.4%. Bollinger Bands are 3.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.16 - 1.17 1.17 - 1.17
Low: 1.1 - 1.1 1.1 - 1.11
Close: 1.15 - 1.16 1.16 - 1.17

Company Description

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Headline News

Mon, 21 Nov 2022
2022-11-21 | NDAQ:CTXR | Press Release | Citius Pharmaceuticals Inc. - Stockhouse

Wed, 09 Nov 2022
Citius Pharmaceuticals Announces Efficacy and Safety Data for its I/ONTAK (E7777) Phase 3 Study for Treatment of Cutaneous T-Cell Lymphoma to be Presented at the 64th American Society of Hematology (ASH) Annual Meeting - Yahoo Finance

Tue, 08 Nov 2022
Citius Pharmaceuticals: Large Price Action Imminent From Catalysts Within 60 Days (CTXR) - Seeking Alpha

Fri, 28 Oct 2022
Citius Pharmaceuticals Inc (CTXR) Stock: What Does the Chart Say Friday? - InvestorsObserver

Tue, 04 Oct 2022
When Can We Expect A Profit From Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)? - Simply Wall St

Wed, 28 Sep 2022
Citius Pharmaceuticals Seeks FDA OK of Reformulated Ontak Drug >CTXR - MarketWatch

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 146 (M)
Shares Float 134 (M)
% Held by Insiders 8.4 (%)
% Held by Institutions 11.1 (%)
Shares Short 10,760 (K)
Shares Short P.Month 11,100 (K)

Stock Financials

EPS -0.21
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.75
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -14.5
Return on Equity (ttm) -24.8
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.22
Qtrly Earnings Growth 0
Operating Cash Flow -28 (M)
Levered Free Cash Flow -56 (M)

Stock Valuations

PE Ratio -5.9
PEG Ratio 0
Price to Book value 1.58
Price to Sales 0
Price to Cash Flow -6.3

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2017-06-08
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.